
Cell Reprogramming & Therapeutics: Pioneering cell reprogramming tech for CNS disease treatment since 2013.
Founded in 2013 and based in Wauwatosa, Wisconsin, Cell Reprogramming & Therapeutics is dedicated to developing advanced cell reprogramming technologies aimed at treating central nervous system (CNS) diseases. The company's core mission is to revolutionize CNS disease treatment by leveraging cutting-edge biotechnological innovations. Their primary focus is on creating therapies that can reprogram cells to restore or replace damaged neural tissues, offering new hope for patients with debilitating neurological conditions.
Notable figures associated with Cell Reprogramming & Therapeutics include leading scientists and biotech experts who have significantly contributed to the field of cell reprogramming. The company has garnered attention from prominent investors in the biotech sector, reflecting confidence in its innovative approach and potential impact. Key achievements include several breakthroughs in cell reprogramming techniques and successful preclinical trials, positioning the company as a pioneer in CNS disease treatment. Their work has the potential to transform therapeutic strategies and improve the quality of life for countless individuals affected by neurological disorders.
Companies similar to Cell Reprogramming & Therapeutics include iReprogram, Retro Biosciences, PolyCore Therapeutics and Autobahn Therapeutics.
Cell Reprogramming & Therapeutics was founded in 2014.
Cell Reprogramming & Therapeutics' headquarters is located in Wauwatosa, WI, US.
Cell Reprogramming & Therapeutics' most recent funding round was for $75k (USD) in June 2022.
As of Jun 7, 2022, Cell Reprogramming & Therapeutics has raised a total of $370k (USD).
Cell Reprogramming & Therapeutics has 5 employees as of Feb 4, 2024.
PolyCore Therapeutics